c103965.htm - Prepared by Imprima

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

December 20, 2010

________________

 

        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 


 

 

Company Announcement

20 December 2010

Novo Nordisk A/S – Share repurchase programme

On 27 October 2010 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.4 billion in the period from 27 October 2010 to 23 December 2010.

Since the announcement as of 13 December 2010, the following transactions have been made under the programme:

 

 

Number of

Average

Transaction value,

 

shares

purchase price

DKK

Accumulated, last

announcement

1,802,000

 

1,024,404,650

13 December 2010

60,000

609.9600

36,597,600

14 December 2010

75,000

607.4199

45,556,493

15 December 2010

75,000

610.2400

45,768,000

16 December 2010

65,000

610.1300

39,658,450

17 December 2010

90,000

619.1915

55,727,235

Accumulated under

the programme

2,167,000

 

1,247,712,428

 

With the transactions stated above, Novo Nordisk owns a total of 28,742,005 treasury shares, corresponding to 4.8% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

 

Company Announcement no 70 / 2010

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 

 


 

 

 

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

 

Further information:

 

 

Media:

Investors:

 

Anne Margrethe Hauge

Tel: (+45) 4442 3450

amhg@novonordisk.com

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

klda@novonordisk.com

 

 

 

 

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

krop@novonordisk.com

 

Jannick Lindegaard

Tel: (+45) 4442 4765

jlis@novonordisk.com

In North America:

Ken Inchausti

Tel: (+1) 609 514 8316

kiau@novonordisk.com

In North America:

Hans Rommer

Tel: (+1) 609 919 7937

hrmm@novonordisk.com

 

Company Announcement no 70 / 2010

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: December 20, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer